Holen Sie sich die Stockscreener-App
7.25
0.68%
-0.05
Vorhandelsmarkt:
7.21
-0.04
-0.55%
Schlusskurs vom Vortag:
$7.30
Offen:
$7.28
24-Stunden-Volumen:
244.20K
Relative Volume:
1.21
Marktkapitalisierung:
$106.06M
Einnahmen:
$53.74M
Nettoeinkommen (Verlust:
$29.82M
KGV:
3.1541
EPS:
2.2986
Netto-Cashflow:
$-33.54M
1W Leistung:
+24.78%
1M Leistung:
+53.28%
6M Leistung:
+285.64%
1J Leistung:
+248.56%
1-Tages-Spanne:
$6.85
$7.525
1-Wochen-Bereich:
$5.51
$7.525
52-Wochen-Spanne:
$1.345
$7.80
Q 32 Bio Inc Stock (QTTB) Company Profile
Firmenname
Q 32 Bio Inc
Sektor
Branche
Telefon
781-999-0232
Adresse
830 WINTER STREET, WALTHAM
Compare QTTB vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
7.25 | 106.06M | 53.74M | 29.82M | -33.54M | 2.2986 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-02-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | Raymond James | Strong Buy |
| 2024-09-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-17 | Eingeleitet | Guggenheim | Buy |
| 2024-05-21 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Piper Sandler | Overweight |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-02-22 | Bestätigt | BTIG Research | Neutral |
| 2022-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-02-22 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2020-12-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-24 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-11-01 | Eingeleitet | Oppenheimer | Perform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Q 32 Bio Inc Aktie (QTTB) Neueste Nachrichten
If You Invested $1,000 in Q32 BIO INC (QTTB) - Stock Titan
Q32 Bio (QTTB) CSO granted 37,500 RSUs and updates holdings - Stock Titan
Q32 Bio (QTTB) awards 53,250 RSUs to its CFO and President - Stock Titan
Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Best Momentum Stocks to Buy for March 19th - The Globe and Mail
Q32 Bio (NASDAQ:QTTB) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
Best Momentum Stocks to Buy for March 13th - The Globe and Mail
Q32 Bio Hits New HighRegrowth Signals? - RTTNews
Q32 Bio, Inc. Experiences Comprehensive Evaluation Adjustment Amid Financial Landscape Changes - Markets Mojo
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (ATRC), Q32 Bio (QTTB) and Shoulder Innovations, Inc. (SI) - The Globe and Mail
FY2026 Earnings Estimate for Q32 Bio Issued By HC Wainwright - MarketBeat
What is HC Wainwright’s Forecast for Q32 Bio Q1 Earnings? - Defense World
Q32 Bio Faces Governance Backlash and Rising Costs After 2025 Stock Option Repricing - The Globe and Mail
Q1 Earnings Estimate for Q32 Bio Issued By HC Wainwright - MarketBeat
H.C. Wainwright Maintains Buy on QTTB Q32 Bio Inc. March 2026 - Meyka
H.C. Wainwright reiterates Q32 Bio stock rating with $13 target - Investing.com India
Q32 Bio Reports Q4 2025 Financial Results, Highlights SIGNAL-AA Trial Progress and Strong Financial Runway into 2027 - Minichart
Q32 Bio Inc. (QTTB) Reports Q4 Earnings - AlphaStreet
Q32 Bio Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Q32 Bio Inc. 2025 Annual Report: Business Overview, Pipeline, Risks, and Intellectual Property Strategies - Minichart
Q32 Bio 2025 Financial Results: Q4 Net Income $57.7M, Revenue $53.7MNews and Statistics - IndexBox
Q32 Bio (NASDAQ:QTTB) Releases Quarterly Earnings Results, Beats Expectations By $4.71 EPS - MarketBeat
Q32 Bio Inc. releases fourth quarter 2025 results and issues corporate update - Traders Union
Q32 Bio 10-K: $53.7M collaboration revenue drives $29.8M net income - TradingView
Q32 Bio: Q4 Earnings Snapshot - kare11.com
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Q32 Bio: Q4 Financial Overview - Bitget
Q32 Bio Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView
Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today - Stocktwits
Q32 Bio (QTTB) Projected to Post Earnings on Tuesday - MarketBeat
QTTB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
QTTB SEC FilingsQ32 BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
Q32 Bio Spotlights Bempikibart AA Data Ahead, Sharpens Focus After Asset Sale at Oppenheimer Confab - MarketBeat
QTTB PE Ratio & Valuation, Is QTTB Overvalued - Intellectia AI
FY2025 Earnings Estimate for Q32 Bio Issued By HC Wainwright - Defense World
Insider Selling: Q32 Bio (NASDAQ:QTTB) CFO Sells 3,995 Shares of Stock - MarketBeat
Insider Selling: Q32 Bio (NASDAQ:QTTB) Insider Sells 2,815 Shares of Stock - MarketBeat
Q32 Bio (QTTB) CSO auto-sells 2,815 shares to cover tax bill - Stock Titan
FY2025 Earnings Forecast for Q32 Bio Issued By HC Wainwright - MarketBeat
Insider Selling: Q32 Bio (NASDAQ:QTTB) CEO Sells $44,630.96 in Stock - MarketBeat
FY2029 Earnings Forecast for Q32 Bio Issued By HC Wainwright - Defense World
Analysts Offer Predictions for Q32 Bio FY2029 Earnings - MarketBeat
Q32 Bio (QTTB) Price Target Increased by 32.35% to 15.30 - Nasdaq
HC Wainwright & Co. Initiates Coverage of Q32 Bio (QTTB) with Buy Recommendation - Nasdaq
H.C. Wainwright initiates Q32 Bio stock coverage with buy rating - Investing.com
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Q32 Bio (NASDAQ:QTTB) Now Covered by Analysts at HC Wainwright - MarketBeat
QTTBQ32 BIO INC Latest Stock News & Market Updates - Stock Titan
Q32 Bio Inc. $QTTB Shares Sold by Monaco Asset Management SAM - MarketBeat
Opaleye Group reports 1.256M shares in Q32 Bio (NASDAQ: QTTB) - Stock Titan
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight (2026-02-19) - Seeking Alpha
Finanzdaten der Q 32 Bio Inc-Aktie (QTTB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):